Adolescent Addiction

Adolescent substance use carries unique developmental risks and demands age-appropriate care models. The session covers the AAP 2024 guideline on adolescent buprenorphine, school-based SBIRT implementation, family-based therapy modalities (BSFT, MDFT, FFT), vaping and high-THC cannabis use, and the rising co-morbidity with adolescent depression, anxiety and ADHD. Discussion includes ED-based peer-recovery programmes, college-campus addiction services, MOSAIC and Teen-LABS adolescent bariatric-comorbidity data, and the rapidly evolving landscape of digital therapeutics targeting adolescent users. Special attention to fentanyl-laced counterfeit pill exposure among teens and the urgent need to expand naloxone in schools and to reduce stigma in paediatric care settings.